Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068448950> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2068448950 endingPage "577" @default.
- W2068448950 startingPage "574" @default.
- W2068448950 abstract "Background. The efficacy and safety of concurrent administration of irinotecan with the two monoclonal antibodies cetuximab and bevacizumab as fourth line therapy in heavily pretreated patients with metastatic colorectal cancer were evaluated. Patients and methods. Patients with metastatic colorectal cancer who had progressed on therapy with 5-FU, oxaliplatin and irinotecan in the first and second line setting and on the combination of irinotecan and cetuximab in third line setting independent of their KRAS mutation status, were treated with irinotecan and cetuximab combined with bevacizumab in a dosage of 5 mg/kg. All drugs were administered every second week. Results. From January 2007 to November 2008 27 patients were treated with cetuximab, irinotecan and bevacizumab. The triple-combination was well tolerated. Progression free survival (PFS) was 8.3 months and median overall survival (mOS) was 12.0 months. Two patients without KRAS mutation (7%) obtained a partial response and 17 (63%) had stable disease for at least two months. A retrospective KRAS mutation analysis revealed that there was a trend toward longer PFS and mOS in patients without KRAS mutations compared to patients with KRAS mutations with a PFS of 8.9 vs. 5.1 months and a mOS of 12.7 vs. 9.0 months. Conclusion. Bevacizumab is safe to add to irinotecan and cetuximab with a toxicity profile that seems to be similar to what would be expected from the agents alone. The results indicate that adding bevacizumab to irinotecan and cetuximab in a fourth line setting may induce a high rate of disease control in heavily pretreated patients with metastatic colorectal cancer." @default.
- W2068448950 created "2016-06-24" @default.
- W2068448950 creator A5004947197 @default.
- W2068448950 creator A5008068706 @default.
- W2068448950 creator A5019680485 @default.
- W2068448950 creator A5022097201 @default.
- W2068448950 creator A5027286810 @default.
- W2068448950 creator A5040287002 @default.
- W2068448950 creator A5050154079 @default.
- W2068448950 creator A5053042879 @default.
- W2068448950 creator A5068848511 @default.
- W2068448950 creator A5081318933 @default.
- W2068448950 creator A5090876784 @default.
- W2068448950 date "2011-05-01" @default.
- W2068448950 modified "2023-09-24" @default.
- W2068448950 title "Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer" @default.
- W2068448950 cites W1976367809 @default.
- W2068448950 cites W2002226820 @default.
- W2068448950 cites W2077129920 @default.
- W2068448950 cites W2097121246 @default.
- W2068448950 cites W2106656437 @default.
- W2068448950 cites W2106789440 @default.
- W2068448950 cites W2110920272 @default.
- W2068448950 cites W2137759849 @default.
- W2068448950 cites W2142564546 @default.
- W2068448950 cites W2155311724 @default.
- W2068448950 cites W2171429059 @default.
- W2068448950 cites W2409420104 @default.
- W2068448950 doi "https://doi.org/10.3109/0284186x.2010.546369" @default.
- W2068448950 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21529301" @default.
- W2068448950 hasPublicationYear "2011" @default.
- W2068448950 type Work @default.
- W2068448950 sameAs 2068448950 @default.
- W2068448950 citedByCount "12" @default.
- W2068448950 countsByYear W20684489502012 @default.
- W2068448950 countsByYear W20684489502013 @default.
- W2068448950 countsByYear W20684489502014 @default.
- W2068448950 countsByYear W20684489502015 @default.
- W2068448950 countsByYear W20684489502016 @default.
- W2068448950 countsByYear W20684489502017 @default.
- W2068448950 countsByYear W20684489502019 @default.
- W2068448950 crossrefType "journal-article" @default.
- W2068448950 hasAuthorship W2068448950A5004947197 @default.
- W2068448950 hasAuthorship W2068448950A5008068706 @default.
- W2068448950 hasAuthorship W2068448950A5019680485 @default.
- W2068448950 hasAuthorship W2068448950A5022097201 @default.
- W2068448950 hasAuthorship W2068448950A5027286810 @default.
- W2068448950 hasAuthorship W2068448950A5040287002 @default.
- W2068448950 hasAuthorship W2068448950A5050154079 @default.
- W2068448950 hasAuthorship W2068448950A5053042879 @default.
- W2068448950 hasAuthorship W2068448950A5068848511 @default.
- W2068448950 hasAuthorship W2068448950A5081318933 @default.
- W2068448950 hasAuthorship W2068448950A5090876784 @default.
- W2068448950 hasConcept C121608353 @default.
- W2068448950 hasConcept C126322002 @default.
- W2068448950 hasConcept C143998085 @default.
- W2068448950 hasConcept C2776694085 @default.
- W2068448950 hasConcept C2777802072 @default.
- W2068448950 hasConcept C2779998722 @default.
- W2068448950 hasConcept C2780259306 @default.
- W2068448950 hasConcept C2780962732 @default.
- W2068448950 hasConcept C2781187634 @default.
- W2068448950 hasConcept C526805850 @default.
- W2068448950 hasConcept C71924100 @default.
- W2068448950 hasConceptScore W2068448950C121608353 @default.
- W2068448950 hasConceptScore W2068448950C126322002 @default.
- W2068448950 hasConceptScore W2068448950C143998085 @default.
- W2068448950 hasConceptScore W2068448950C2776694085 @default.
- W2068448950 hasConceptScore W2068448950C2777802072 @default.
- W2068448950 hasConceptScore W2068448950C2779998722 @default.
- W2068448950 hasConceptScore W2068448950C2780259306 @default.
- W2068448950 hasConceptScore W2068448950C2780962732 @default.
- W2068448950 hasConceptScore W2068448950C2781187634 @default.
- W2068448950 hasConceptScore W2068448950C526805850 @default.
- W2068448950 hasConceptScore W2068448950C71924100 @default.
- W2068448950 hasIssue "4" @default.
- W2068448950 hasLocation W20684489501 @default.
- W2068448950 hasLocation W20684489502 @default.
- W2068448950 hasOpenAccess W2068448950 @default.
- W2068448950 hasPrimaryLocation W20684489501 @default.
- W2068448950 hasRelatedWork W2002226820 @default.
- W2068448950 hasRelatedWork W2106656437 @default.
- W2068448950 hasRelatedWork W2127640925 @default.
- W2068448950 hasRelatedWork W2142564546 @default.
- W2068448950 hasRelatedWork W2155311724 @default.
- W2068448950 hasVolume "50" @default.
- W2068448950 isParatext "false" @default.
- W2068448950 isRetracted "false" @default.
- W2068448950 magId "2068448950" @default.
- W2068448950 workType "article" @default.